BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 2015;6:17147-60. [PMID: 26003166 DOI: 10.18632/oncotarget.3940] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Jin L, Liu WR, Tian MX, Jiang XF, Wang H, Zhou PY, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Fan J, Shi YH. CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget 2017;8:5135-48. [PMID: 28042950 DOI: 10.18632/oncotarget.14095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
2 Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget 2017;8:76525-57. [PMID: 29100331 DOI: 10.18632/oncotarget.20408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
3 Arora M, Kutinová Canová N, Farghali H. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174857] [Reference Citation Analysis]
4 Martorana A, La Monica G, Lauria A. Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways. Molecules 2020;25:E4279. [PMID: 32961977 DOI: 10.3390/molecules25184279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hao T, Li Y, Fan S, Li W, Wang S, Li S, Cao R, Zhong W. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur J Med Chem 2019;175:172-86. [PMID: 31082764 DOI: 10.1016/j.ejmech.2019.04.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Zhang J, Wang G, Zhou Y, Chen Y, Ouyang L, Liu B. Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy. Cell Mol Life Sci 2018;75:1803-26. [PMID: 29417176 DOI: 10.1007/s00018-018-2759-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
7 Lee YG, Jeon TI. Modulation of the Autophagy-lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. Molecules 2020;25:E1580. [PMID: 32235537 DOI: 10.3390/molecules25071580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G, Cervello M, Polesel J. Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochim Biophys Acta. 2016;1863:438-448. [PMID: 26278055 DOI: 10.1016/j.bbamcr.2015.08.010] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
9 Simioni C, Conti I, Varano G, Brenna C, Costanzi E, Neri LM. The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies. Front Oncol 2021;11:673506. [PMID: 34026651 DOI: 10.3389/fonc.2021.673506] [Reference Citation Analysis]
10 Ding Z, Shi C, Jiang L, Tolstykh T, Cao H, Bangari DS, Ryan S, Levit M, Jin T, Mamaat K, Yu Q, Qu H, Hopke J, Cindhuchao M, Hoffmann D, Sun F, Helms MW, Jahn-Hofmann K, Scheidler S, Schweizer L, Fang DD, Pollard J, Winter C, Wiederschain D. Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation. Oncotarget 2017;8:114526-39. [PMID: 29383099 DOI: 10.18632/oncotarget.21298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
11 Han B, Yu YQ, Yang QL, Shen CY, Wang XJ. Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling. Oncotarget 2017;8:86227-39. [PMID: 29156790 DOI: 10.18632/oncotarget.21043] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
12 Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget 2016;7:79842-53. [PMID: 27821800 DOI: 10.18632/oncotarget.13035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
13 Recinella L, Chiavaroli A, Masciulli F, Fraschetti C, Filippi A, Cesa S, Cairone F, Gorica E, De Leo M, Braca A, Martelli A, Calderone V, Orlando G, Ferrante C, Menghini L, Di Simone SC, Veschi S, Cama A, Brunetti L, Leone S. Protective Effects Induced by a Hydroalcoholic Allium sativum Extract in Isolated Mouse Heart. Nutrients 2021;13:2332. [PMID: 34371842 DOI: 10.3390/nu13072332] [Reference Citation Analysis]
14 Chen L, Tian H, Li M, Ge C, Zhao F, Zhang L, Li H, Liu J, Wang T, Yao M, Li J. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. Tumour Biol 2016;37:5951-61. [PMID: 26596832 DOI: 10.1007/s13277-015-4362-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
15 He S, Li Q, Jiang X, Lu X, Feng F, Qu W, Chen Y, Sun H. Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy. J Med Chem 2018;61:4656-87. [PMID: 29211480 DOI: 10.1021/acs.jmedchem.7b01019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
16 Chen Y, Zhou X. Research progress of mTOR inhibitors. Eur J Med Chem 2020;208:112820. [PMID: 32966896 DOI: 10.1016/j.ejmech.2020.112820] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
17 Mediani L, Gibellini F, Bertacchini J, Frasson C, Bosco R, Accordi B, Basso G, Bonora M, Calabrò ML, Mattiolo A, Sgarbi G, Baracca A, Pinton P, Riva G, Rampazzo E, Petrizza L, Prodi L, Milani D, Luppi M, Potenza L, De Pol A, Cocco L, Capitani S, Marmiroli S. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. Oncotarget 2016;7:5521-37. [PMID: 26575168 DOI: 10.18632/oncotarget.6315] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
18 Martelli AM, Buontempo F, McCubrey JA. Drug discovery targeting the mTOR pathway. Clin Sci (Lond) 2018;132:543-68. [PMID: 29523752 DOI: 10.1042/CS20171158] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 10.8] [Reference Citation Analysis]
19 Yao S, Tian C, Ding Y, Ye Q, Gao Y, Yang N, Li Q. Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1. Oncotarget 2016;7:42566-78. [PMID: 27302923 DOI: 10.18632/oncotarget.9934] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
20 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
21 Kocak M, Ezazi Erdi S, Jorba G, Maestro I, Farrés J, Kirkin V, Martinez A, Pless O. Targeting autophagy in disease: established and new strategies. Autophagy 2021;:1-23. [PMID: 34241570 DOI: 10.1080/15548627.2021.1936359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 McRee AJ, Sanoff HK, Carlson C, Ivanova A, O'Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs 2015;33:1225-31. [PMID: 26490655 DOI: 10.1007/s10637-015-0298-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
23 Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int 2021;21:208. [PMID: 33849569 DOI: 10.1186/s12935-021-01924-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Alameen AA, Simioni C, Martelli AM, Zauli G, Ultimo S, McCubrey JA, Gonelli A, Marisi G, Ulivi P, Capitani S, Neri LM. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget 2016;7:55690-703. [PMID: 27494886 DOI: 10.18632/oncotarget.10984] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]